Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.74 |
| ▸ | CTSS | P25774 | 4/20 | 0.69 |
| ▸ | PPARG | P37231 | 2/20 | 0.67 |
| ▸ | KLK7 | P49862 | 2/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 4/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2728641 | 1.00 | PPARA (0.74) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL3893943 | 1.00 | PPARA (0.74) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL7057256 | 0.91 | PPARA (0.76) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL29229102 | 0.91 | PPARA (0.76) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL1132901 | 0.90 | PPARA (0.90) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL17051 | 0.90 | PPARA (0.90) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL828674 | 0.90 | PPARA (0.90) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL12432974 | 0.88 | PPARA (0.68) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL11901546 | 0.88 | PPARA (0.64) | PPARACTSSPPARGKLK7KLK5 | |
| SCHEMBL824968 | 0.88 | CTSS (0.73) | PPARACTSSPPARGKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2397488-B1 | DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS | FEDERAL STATE BUDGETARY INSTITUTION RES ZAKUSOV INSTITUTE OF PHARMACOLOGY (RU) | 2019-03-27 | — | — | EP | disclosed |
| US-9902688-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| EP-2570414-B1 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | BRISTOL MYERS SQUIBB CO (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9683014-B2 | Dipeptide mimetics of NGF and BDNF neurotrophins | UCHREZHDENIE ROSSIISKOI AKADEMII MEDITSYNSKIKH NAUK NAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII IMENI V.V.ZAKUSOVA RAMN (RU) | 2017-06-20 | — | — | US | disclosed |
| EP-3176154-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20160318852-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9359375-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150111828-A1 | DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS | UCHREZHDENIE ROSSIISKOI AKADEMII MEDITSYNSKIKH NAUK NAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII (RU) | 2015-04-23 | — | — | US | disclosed |
| US-20150038492-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8846928-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2635556-A2 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2012061418-A2 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20110312895-A1 | DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS | UCHREZHDENIE ROSSIISKOI AKADEMII MEDITSYNSKIKH NAUK NAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII IMENI V.V.ZAKUSOVA RAMN (RU) | 2011-12-22 | — | — | US | disclosed |
| EP-2397488-A1 | DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS | Uchrezhdenie Rossiiskoi Akademii Meditsynskikh Nauk Nauchno-issledovatelsky Institut Farmakologii Imeni V.V.Zakusova Ramn (RU) | 2011-12-21 | — | — | EP | disclosed |
| EP-1399431-B1 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | PPARA 1246/4885CTSS 1406/4885PPARG 1954/4885 |
| US-20150111828-A1 | DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS | BDNF, NTRK2, NGF | PPARA 2345/4885CTSS 3014/4885PPARG 2618/4885 |
| US-20160318852-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | PPARA 1246/4885CTSS 1406/4885PPARG 1954/4885 |
| US-20110312895-A1 | DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS | BDNF, NTRK2, NGF | PPARA 2345/4885CTSS 3014/4885PPARG 2618/4885 |
| US-20150038492-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | PPARA 1246/4885CTSS 1406/4885PPARG 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.